SpainThe Spanish government has approved a new pharmaceutical law that allows generic drugs to compete on price, potentially leading to lower costs for the public healthcare system while allowing patients to choose branded medications at higher prices. Under this law, the Ministry of Health will set a maximum financed amount, enabling generic drug manufacturers to bid competitively for market share. Patients who prefer branded medications will pay the difference. The goal is to increase the penetration of generics and reduce overall pharmaceutical costs. The current reference pricing system has led to higher prices for generics in Spain compared to wealthier countries like Sweden. The law now moves to Congress for final approval, which could be influenced by political parties such as the PP and Junts. The legislation also introduces 'strategic medicines' to ensure supply chain resilience and includes measures to prevent shortages. A dynamic pricing system will complement the existing reference pricing model.
Bias read (Center): The article presents the legislative changes objectively, detailing both the potential benefits for cost reduction and the implications for patient choice. It does not overtly favor either side politically but reports on the policy shift and its possible impacts across different stakeholders. The ph
